Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukoencephalopathy, Progressive Multifocal | 93 | 2021 | 98 | 23.440 |
Why?
|
JC Virus | 79 | 2021 | 81 | 18.520 |
Why?
|
CD8-Positive T-Lymphocytes | 13 | 2023 | 101 | 3.940 |
Why?
|
HIV Infections | 33 | 2022 | 432 | 3.750 |
Why?
|
Polyomavirus Infections | 20 | 2018 | 23 | 3.670 |
Why?
|
DNA, Viral | 20 | 2019 | 36 | 3.300 |
Why?
|
Humans | 182 | 2023 | 25212 | 3.200 |
Why?
|
Antibodies, Monoclonal, Humanized | 11 | 2021 | 87 | 3.090 |
Why?
|
Capsid Proteins | 16 | 2019 | 20 | 2.910 |
Why?
|
Neurons | 10 | 2019 | 288 | 2.760 |
Why?
|
Brain | 30 | 2020 | 1629 | 2.650 |
Why?
|
AIDS-Related Opportunistic Infections | 11 | 2015 | 37 | 2.600 |
Why?
|
Nervous System Diseases | 6 | 2021 | 116 | 2.530 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 8 | 2017 | 10 | 2.420 |
Why?
|
CD4-Positive T-Lymphocytes | 11 | 2023 | 103 | 2.410 |
Why?
|
Brain Diseases | 8 | 2021 | 66 | 2.360 |
Why?
|
Seizures | 13 | 2022 | 63 | 2.270 |
Why?
|
Multiple Sclerosis | 8 | 2020 | 77 | 2.260 |
Why?
|
Adult | 69 | 2022 | 7089 | 2.260 |
Why?
|
T-Lymphocytes, Cytotoxic | 13 | 2009 | 21 | 2.150 |
Why?
|
Male | 89 | 2022 | 13562 | 2.140 |
Why?
|
Tuberculosis, Meningeal | 3 | 2021 | 3 | 2.110 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 7 | 2021 | 21 | 1.990 |
Why?
|
Acquired Immunodeficiency Syndrome | 11 | 2015 | 44 | 1.940 |
Why?
|
Neurology | 4 | 2022 | 54 | 1.850 |
Why?
|
Female | 70 | 2022 | 13863 | 1.710 |
Why?
|
Middle Aged | 55 | 2022 | 8144 | 1.690 |
Why?
|
Disease Progression | 15 | 2023 | 650 | 1.590 |
Why?
|
HIV Seropositivity | 9 | 2013 | 46 | 1.550 |
Why?
|
Immunity, Cellular | 9 | 2013 | 31 | 1.500 |
Why?
|
Magnetic Resonance Imaging | 28 | 2020 | 1113 | 1.430 |
Why?
|
Fatigue | 4 | 2023 | 55 | 1.350 |
Why?
|
Antibodies, Viral | 11 | 2023 | 50 | 1.310 |
Why?
|
Spinal Cord | 4 | 2015 | 79 | 1.290 |
Why?
|
Remote Consultation | 2 | 2022 | 11 | 1.290 |
Why?
|
Zambia | 15 | 2022 | 15 | 1.290 |
Why?
|
Coronavirus Infections | 2 | 2020 | 81 | 1.270 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 84 | 1.260 |
Why?
|
Simian virus 40 | 6 | 2015 | 7 | 1.260 |
Why?
|
Natalizumab | 11 | 2019 | 15 | 1.250 |
Why?
|
Immunologic Factors | 5 | 2021 | 29 | 1.200 |
Why?
|
Antibodies, Monoclonal | 5 | 2022 | 195 | 1.190 |
Why?
|
Cerebral Cortex | 4 | 2014 | 161 | 1.120 |
Why?
|
BK Virus | 8 | 2014 | 11 | 1.120 |
Why?
|
Sequence Deletion | 4 | 2012 | 12 | 1.110 |
Why?
|
Cerebellum | 6 | 2013 | 42 | 1.020 |
Why?
|
Young Adult | 16 | 2021 | 1751 | 1.020 |
Why?
|
Tumor Virus Infections | 7 | 2014 | 14 | 1.010 |
Why?
|
Aged | 34 | 2021 | 8421 | 1.000 |
Why?
|
HIV Seronegativity | 5 | 2014 | 16 | 0.990 |
Why?
|
Viral Proteins | 4 | 2015 | 10 | 0.940 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 4 | 2015 | 15 | 0.920 |
Why?
|
Cognitive Dysfunction | 3 | 2023 | 1013 | 0.910 |
Why?
|
Headache | 2 | 2021 | 33 | 0.900 |
Why?
|
Histocompatibility Antigens Class I | 3 | 2015 | 18 | 0.890 |
Why?
|
Capsid | 5 | 2014 | 10 | 0.890 |
Why?
|
Viral Regulatory and Accessory Proteins | 4 | 2013 | 13 | 0.890 |
Why?
|
Mitochondrial Proteins | 1 | 2023 | 19 | 0.890 |
Why?
|
Antigens, Viral, Tumor | 7 | 2019 | 8 | 0.880 |
Why?
|
Genotype | 2 | 2021 | 338 | 0.870 |
Why?
|
Olfaction Disorders | 2 | 2020 | 49 | 0.870 |
Why?
|
Narcolepsy | 2 | 2019 | 4 | 0.850 |
Why?
|
Kidney Transplantation | 7 | 2017 | 112 | 0.830 |
Why?
|
HIV-1 | 7 | 2017 | 210 | 0.830 |
Why?
|
Internship and Residency | 2 | 2017 | 196 | 0.830 |
Why?
|
Betacoronavirus | 2 | 2020 | 69 | 0.830 |
Why?
|
HIV-2 | 3 | 2017 | 11 | 0.830 |
Why?
|
Regulatory Sequences, Nucleic Acid | 4 | 2008 | 7 | 0.820 |
Why?
|
Substance Withdrawal Syndrome | 2 | 2012 | 33 | 0.810 |
Why?
|
Oligodendroglia | 4 | 2019 | 23 | 0.800 |
Why?
|
Viral Load | 12 | 2020 | 71 | 0.800 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2019 | 8 | 0.790 |
Why?
|
Interferon-gamma | 2 | 2019 | 59 | 0.790 |
Why?
|
Molecular Sequence Data | 16 | 2012 | 173 | 0.780 |
Why?
|
Epoxide Hydrolases | 1 | 2021 | 10 | 0.780 |
Why?
|
Anticonvulsants | 4 | 2020 | 59 | 0.780 |
Why?
|
Dizziness | 2 | 2023 | 18 | 0.780 |
Why?
|
Retrospective Studies | 15 | 2023 | 3105 | 0.770 |
Why?
|
Animals | 19 | 2023 | 3381 | 0.740 |
Why?
|
Dysgeusia | 1 | 2020 | 1 | 0.730 |
Why?
|
Myalgia | 1 | 2020 | 1 | 0.730 |
Why?
|
Orexins | 2 | 2019 | 3 | 0.730 |
Why?
|
Choroid Plexus | 2 | 2021 | 6 | 0.710 |
Why?
|
Prospective Studies | 9 | 2023 | 1591 | 0.710 |
Why?
|
Coinfection | 4 | 2019 | 20 | 0.690 |
Why?
|
Astrocytes | 3 | 2021 | 113 | 0.690 |
Why?
|
Autoimmunity | 1 | 2019 | 8 | 0.680 |
Why?
|
Virus Latency | 2 | 2010 | 13 | 0.680 |
Why?
|
Dimethyl Fumarate | 2 | 2019 | 2 | 0.680 |
Why?
|
Meninges | 2 | 2019 | 7 | 0.680 |
Why?
|
T-Lymphocytes | 6 | 2014 | 87 | 0.670 |
Why?
|
Global Health | 2 | 2017 | 39 | 0.660 |
Why?
|
Henipavirus Infections | 1 | 2019 | 1 | 0.660 |
Why?
|
Immunoassay | 1 | 2019 | 33 | 0.660 |
Why?
|
Telemedicine | 1 | 2021 | 94 | 0.660 |
Why?
|
Quality of Life | 5 | 2023 | 595 | 0.650 |
Why?
|
Lipopolysaccharides | 1 | 2019 | 95 | 0.650 |
Why?
|
Follow-Up Studies | 10 | 2022 | 1622 | 0.650 |
Why?
|
Antiretroviral Therapy, Highly Active | 7 | 2019 | 57 | 0.650 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 174 | 0.640 |
Why?
|
Virus Activation | 4 | 2014 | 11 | 0.630 |
Why?
|
Inflammation | 4 | 2020 | 255 | 0.630 |
Why?
|
Survivors | 3 | 2015 | 50 | 0.620 |
Why?
|
Bone Marrow | 2 | 2009 | 73 | 0.620 |
Why?
|
Anti-Retroviral Agents | 2 | 2015 | 16 | 0.610 |
Why?
|
Amino Acid Sequence | 11 | 2012 | 136 | 0.600 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2018 | 41 | 0.600 |
Why?
|
HLA-A Antigens | 6 | 2010 | 13 | 0.580 |
Why?
|
Polymerase Chain Reaction | 11 | 2014 | 111 | 0.580 |
Why?
|
Case-Control Studies | 6 | 2021 | 541 | 0.580 |
Why?
|
Meningitis, Aseptic | 2 | 2014 | 3 | 0.570 |
Why?
|
Neuroglia | 3 | 2021 | 36 | 0.570 |
Why?
|
Health Resources | 1 | 2017 | 20 | 0.560 |
Why?
|
Program Development | 1 | 2017 | 58 | 0.550 |
Why?
|
Cerebellar Diseases | 2 | 2018 | 7 | 0.550 |
Why?
|
Anti-HIV Agents | 5 | 2020 | 63 | 0.540 |
Why?
|
Genes, Viral | 3 | 2018 | 4 | 0.530 |
Why?
|
Human T-lymphotropic virus 1 | 7 | 1997 | 9 | 0.530 |
Why?
|
Thymus Gland | 1 | 2015 | 11 | 0.520 |
Why?
|
Biomarkers | 6 | 2022 | 550 | 0.520 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2013 | 14 | 0.520 |
Why?
|
Aged, 80 and over | 11 | 2020 | 4512 | 0.510 |
Why?
|
Virus Diseases | 2 | 2021 | 9 | 0.510 |
Why?
|
Luminescent Proteins | 1 | 2015 | 8 | 0.510 |
Why?
|
Genes, Reporter | 1 | 2015 | 20 | 0.510 |
Why?
|
Prognosis | 8 | 2021 | 727 | 0.500 |
Why?
|
Psoriasis | 1 | 2015 | 11 | 0.500 |
Why?
|
Rare Diseases | 1 | 2015 | 11 | 0.500 |
Why?
|
Dura Mater | 1 | 2015 | 17 | 0.500 |
Why?
|
Lymphopenia | 4 | 2019 | 5 | 0.490 |
Why?
|
Epitopes, T-Lymphocyte | 3 | 2005 | 7 | 0.490 |
Why?
|
Stroke | 4 | 2022 | 254 | 0.490 |
Why?
|
Fatal Outcome | 9 | 2016 | 48 | 0.490 |
Why?
|
Pandemics | 3 | 2022 | 233 | 0.480 |
Why?
|
Adolescent | 10 | 2019 | 1998 | 0.480 |
Why?
|
Viremia | 2 | 2011 | 10 | 0.470 |
Why?
|
Hydrocephalus | 1 | 2014 | 19 | 0.470 |
Why?
|
HIV | 4 | 2019 | 35 | 0.470 |
Why?
|
Central Nervous System Neoplasms | 2 | 2007 | 11 | 0.470 |
Why?
|
Opportunistic Infections | 4 | 2009 | 7 | 0.470 |
Why?
|
Herpesviridae | 1 | 2014 | 1 | 0.470 |
Why?
|
Central Nervous System Infections | 1 | 2014 | 3 | 0.470 |
Why?
|
Risk Factors | 9 | 2020 | 2171 | 0.460 |
Why?
|
DNA | 1 | 2014 | 89 | 0.460 |
Why?
|
Virus Assembly | 1 | 2013 | 1 | 0.450 |
Why?
|
Methylprednisolone | 2 | 2016 | 20 | 0.450 |
Why?
|
Virion | 1 | 2013 | 12 | 0.450 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2013 | 10 | 0.450 |
Why?
|
Spinocerebellar Degenerations | 1 | 2013 | 3 | 0.450 |
Why?
|
ABO Blood-Group System | 1 | 2013 | 5 | 0.450 |
Why?
|
Bacterial Infections | 1 | 2014 | 50 | 0.450 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2013 | 12 | 0.430 |
Why?
|
Polyomavirus | 4 | 2011 | 5 | 0.430 |
Why?
|
Pyramidal Cells | 2 | 2012 | 27 | 0.430 |
Why?
|
Kidney Diseases | 4 | 2008 | 96 | 0.420 |
Why?
|
Arthritis, Rheumatoid | 2 | 2013 | 233 | 0.410 |
Why?
|
Virus Replication | 6 | 2013 | 48 | 0.410 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2014 | 109 | 0.410 |
Why?
|
Cell Line | 7 | 2021 | 240 | 0.400 |
Why?
|
AIDS Dementia Complex | 3 | 2022 | 35 | 0.400 |
Why?
|
Base Sequence | 9 | 2012 | 86 | 0.400 |
Why?
|
Adrenal Cortex Hormones | 1 | 2012 | 94 | 0.390 |
Why?
|
Encephalitis | 3 | 2020 | 10 | 0.390 |
Why?
|
Toxoplasmosis, Cerebral | 1 | 2011 | 1 | 0.390 |
Why?
|
Delayed Diagnosis | 1 | 2011 | 11 | 0.390 |
Why?
|
Survival Rate | 4 | 2021 | 310 | 0.380 |
Why?
|
Tandem Repeat Sequences | 3 | 2012 | 3 | 0.370 |
Why?
|
Phenotype | 2 | 2013 | 285 | 0.360 |
Why?
|
Neurosyphilis | 2 | 2021 | 3 | 0.360 |
Why?
|
Treponema pallidum | 2 | 2021 | 4 | 0.360 |
Why?
|
Genome, Viral | 3 | 2012 | 6 | 0.350 |
Why?
|
Antiviral Agents | 5 | 2015 | 67 | 0.350 |
Why?
|
Developing Countries | 1 | 2010 | 12 | 0.350 |
Why?
|
Immune Tolerance | 1 | 2009 | 11 | 0.340 |
Why?
|
Communicable Diseases | 1 | 2010 | 20 | 0.340 |
Why?
|
COS Cells | 3 | 2014 | 35 | 0.340 |
Why?
|
Integrin alpha4 | 1 | 2009 | 2 | 0.340 |
Why?
|
Immunohistochemistry | 5 | 2019 | 300 | 0.340 |
Why?
|
HLA-A2 Antigen | 3 | 2008 | 3 | 0.340 |
Why?
|
Terminology as Topic | 2 | 2006 | 30 | 0.320 |
Why?
|
Prevalence | 4 | 2021 | 421 | 0.320 |
Why?
|
Kidney | 4 | 2017 | 151 | 0.320 |
Why?
|
Hospitals | 1 | 2010 | 145 | 0.320 |
Why?
|
Dendritic Cells | 1 | 2008 | 24 | 0.320 |
Why?
|
Diagnosis, Differential | 5 | 2023 | 332 | 0.310 |
Why?
|
Lymphoma | 2 | 2007 | 37 | 0.310 |
Why?
|
Genetic Variation | 2 | 2006 | 98 | 0.300 |
Why?
|
Electroencephalography | 5 | 2015 | 81 | 0.300 |
Why?
|
Ataxia | 2 | 2020 | 77 | 0.300 |
Why?
|
Neurologic Examination | 4 | 2013 | 111 | 0.290 |
Why?
|
Neuroimaging | 5 | 2021 | 133 | 0.290 |
Why?
|
Child | 6 | 2022 | 1232 | 0.290 |
Why?
|
Disease Models, Animal | 5 | 2015 | 512 | 0.280 |
Why?
|
Time Factors | 4 | 2014 | 1329 | 0.280 |
Why?
|
Mycobacterium tuberculosis | 2 | 2019 | 15 | 0.280 |
Why?
|
CD4 Lymphocyte Count | 5 | 2020 | 49 | 0.280 |
Why?
|
Immunotherapy | 3 | 2016 | 51 | 0.270 |
Why?
|
Immunosuppressive Agents | 4 | 2019 | 119 | 0.270 |
Why?
|
Antibody Formation | 1 | 2006 | 17 | 0.270 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2012 | 42 | 0.260 |
Why?
|
Epilepsy | 2 | 2020 | 62 | 0.250 |
Why?
|
Nervous System | 2 | 2019 | 9 | 0.250 |
Why?
|
Autopsy | 2 | 2019 | 336 | 0.250 |
Why?
|
Cells, Cultured | 5 | 2008 | 468 | 0.250 |
Why?
|
Sequence Alignment | 4 | 2011 | 16 | 0.250 |
Why?
|
Immunocompromised Host | 4 | 2017 | 43 | 0.240 |
Why?
|
Hepatitis C | 1 | 2005 | 41 | 0.240 |
Why?
|
Recombination, Genetic | 2 | 2015 | 5 | 0.240 |
Why?
|
Inositol | 1 | 2004 | 7 | 0.240 |
Why?
|
Capillary Leak Syndrome | 1 | 2004 | 1 | 0.240 |
Why?
|
Macaca mulatta | 5 | 2013 | 50 | 0.240 |
Why?
|
Aspartic Acid | 1 | 2004 | 14 | 0.240 |
Why?
|
Hematologic Neoplasms | 2 | 2014 | 17 | 0.230 |
Why?
|
Paresis | 1 | 2004 | 10 | 0.230 |
Why?
|
Treatment Outcome | 8 | 2021 | 3147 | 0.230 |
Why?
|
Liver Transplantation | 1 | 2005 | 63 | 0.230 |
Why?
|
Simian Immunodeficiency Virus | 3 | 2013 | 14 | 0.230 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2010 | 26 | 0.230 |
Why?
|
Mice | 6 | 2023 | 1198 | 0.230 |
Why?
|
Genes, pX | 3 | 1997 | 3 | 0.220 |
Why?
|
Chicago | 3 | 2022 | 785 | 0.220 |
Why?
|
Immunity | 1 | 2023 | 16 | 0.220 |
Why?
|
Antigens, Viral | 3 | 2013 | 8 | 0.220 |
Why?
|
Biopsy | 5 | 2017 | 191 | 0.220 |
Why?
|
Proteome | 1 | 2023 | 41 | 0.220 |
Why?
|
Endogenous Retroviruses | 1 | 2003 | 2 | 0.220 |
Why?
|
Ki-1 Antigen | 1 | 2003 | 2 | 0.220 |
Why?
|
Interleukin-6 | 1 | 2023 | 68 | 0.210 |
Why?
|
Lymphoproliferative Disorders | 1 | 2003 | 13 | 0.210 |
Why?
|
Nucleocapsid | 1 | 2022 | 2 | 0.210 |
Why?
|
Dysarthria | 1 | 2022 | 2 | 0.210 |
Why?
|
2',3'-Cyclic-Nucleotide Phosphodiesterases | 2 | 2015 | 4 | 0.210 |
Why?
|
Proteomics | 1 | 2023 | 87 | 0.210 |
Why?
|
Meningitis, Cryptococcal | 1 | 2022 | 2 | 0.210 |
Why?
|
Leukocytes | 2 | 2019 | 28 | 0.210 |
Why?
|
Skin Diseases | 1 | 2003 | 22 | 0.210 |
Why?
|
Meningitis | 1 | 2022 | 8 | 0.210 |
Why?
|
Interferon-beta | 2 | 2014 | 5 | 0.210 |
Why?
|
Deglutition Disorders | 1 | 2022 | 36 | 0.210 |
Why?
|
Cytotoxicity Tests, Immunologic | 4 | 2008 | 7 | 0.200 |
Why?
|
Delirium | 1 | 2022 | 10 | 0.200 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 467 | 0.200 |
Why?
|
Epitopes | 3 | 2008 | 40 | 0.200 |
Why?
|
Transcription Factors | 3 | 2004 | 150 | 0.200 |
Why?
|
Crotonates | 1 | 2021 | 3 | 0.200 |
Why?
|
Toluidines | 1 | 2021 | 3 | 0.200 |
Why?
|
DNA Viruses | 1 | 2021 | 5 | 0.200 |
Why?
|
Transfection | 2 | 2014 | 99 | 0.200 |
Why?
|
Nitriles | 1 | 2021 | 11 | 0.190 |
Why?
|
Hydroxybutyrates | 1 | 2021 | 5 | 0.190 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 1 | 2021 | 2 | 0.190 |
Why?
|
Adoptive Transfer | 1 | 2021 | 20 | 0.190 |
Why?
|
Drug Resistance, Viral | 2 | 2020 | 13 | 0.190 |
Why?
|
Demyelinating Diseases | 3 | 2021 | 9 | 0.190 |
Why?
|
New York City | 1 | 2021 | 14 | 0.190 |
Why?
|
Predictive Value of Tests | 2 | 2013 | 438 | 0.190 |
Why?
|
Herpesviridae Infections | 1 | 2001 | 1 | 0.190 |
Why?
|
Lymphomatoid Papulosis | 1 | 2001 | 1 | 0.190 |
Why?
|
Herpesvirus 8, Human | 1 | 2001 | 1 | 0.190 |
Why?
|
Herpesvirus 7, Human | 1 | 2001 | 2 | 0.190 |
Why?
|
Herpesvirus 6, Human | 1 | 2001 | 3 | 0.190 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2000 | 2 | 0.190 |
Why?
|
Pharmacovigilance | 1 | 2020 | 1 | 0.190 |
Why?
|
Dyskinesias | 1 | 2021 | 23 | 0.190 |
Why?
|
Intracranial Embolism | 1 | 2020 | 3 | 0.190 |
Why?
|
Lymphoma, B-Cell | 1 | 2000 | 9 | 0.180 |
Why?
|
Morbidity | 1 | 2021 | 56 | 0.180 |
Why?
|
Bayes Theorem | 1 | 2021 | 37 | 0.180 |
Why?
|
Peripheral Nerve Injuries | 1 | 2020 | 15 | 0.180 |
Why?
|
Carbamazepine | 1 | 2020 | 6 | 0.180 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 280 | 0.180 |
Why?
|
Meningitis, Viral | 1 | 2020 | 1 | 0.180 |
Why?
|
Leukoencephalitis, Acute Hemorrhagic | 1 | 2020 | 2 | 0.180 |
Why?
|
Guillain-Barre Syndrome | 1 | 2020 | 2 | 0.180 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2000 | 33 | 0.180 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2020 | 4 | 0.180 |
Why?
|
Encephalomyelitis, Acute Disseminated | 1 | 2020 | 3 | 0.180 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 2020 | 4 | 0.180 |
Why?
|
Thrombophilia | 1 | 2020 | 5 | 0.180 |
Why?
|
Cell Count | 3 | 2015 | 67 | 0.180 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 13 | 0.180 |
Why?
|
Neuroprotective Agents | 1 | 2020 | 47 | 0.180 |
Why?
|
Mortality | 1 | 2020 | 81 | 0.170 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 69 | 0.170 |
Why?
|
Cross-Sectional Studies | 3 | 2019 | 836 | 0.170 |
Why?
|
Risk | 2 | 2013 | 195 | 0.170 |
Why?
|
Meningoencephalitis | 2 | 2013 | 5 | 0.170 |
Why?
|
Drugs, Essential | 1 | 2019 | 1 | 0.170 |
Why?
|
World Health Organization | 1 | 2019 | 11 | 0.170 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2019 | 10 | 0.170 |
Why?
|
Consensus | 3 | 2023 | 83 | 0.170 |
Why?
|
Gene Rearrangement | 2 | 2010 | 9 | 0.170 |
Why?
|
Respiration, Artificial | 1 | 2020 | 102 | 0.170 |
Why?
|
Olive Oil | 1 | 2019 | 2 | 0.170 |
Why?
|
Reagent Strips | 1 | 2019 | 3 | 0.170 |
Why?
|
Transplantation, Homologous | 2 | 2014 | 249 | 0.170 |
Why?
|
Movement Disorders | 1 | 2020 | 90 | 0.170 |
Why?
|
Urine | 2 | 2009 | 7 | 0.170 |
Why?
|
Brain Ischemia | 1 | 2020 | 59 | 0.170 |
Why?
|
Glutamate Decarboxylase | 1 | 2019 | 2 | 0.170 |
Why?
|
Cerebellar Cortex | 1 | 2019 | 6 | 0.170 |
Why?
|
Seroepidemiologic Studies | 1 | 2019 | 18 | 0.170 |
Why?
|
Glucose | 1 | 2019 | 49 | 0.160 |
Why?
|
Filgrastim | 1 | 2019 | 3 | 0.160 |
Why?
|
Severity of Illness Index | 2 | 2020 | 903 | 0.160 |
Why?
|
Delivery of Health Care | 2 | 2022 | 142 | 0.160 |
Why?
|
Macaca fascicularis | 2 | 2015 | 19 | 0.160 |
Why?
|
Oncogene Proteins, Viral | 2 | 1995 | 5 | 0.160 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 85 | 0.160 |
Why?
|
Attention | 1 | 2019 | 122 | 0.150 |
Why?
|
Gene Expression | 1 | 2019 | 176 | 0.150 |
Why?
|
Fluorescent Antibody Technique | 2 | 2015 | 51 | 0.150 |
Why?
|
Viral Structural Proteins | 2 | 2009 | 3 | 0.150 |
Why?
|
Reproducibility of Results | 2 | 2019 | 642 | 0.150 |
Why?
|
Cerebrospinal Fluid | 3 | 2009 | 10 | 0.150 |
Why?
|
RNA, Viral | 4 | 2022 | 40 | 0.150 |
Why?
|
Mianserin | 4 | 2016 | 9 | 0.150 |
Why?
|
Mass Screening | 3 | 2015 | 161 | 0.150 |
Why?
|
Bell Palsy | 1 | 2017 | 2 | 0.150 |
Why?
|
Recurrence | 5 | 2018 | 291 | 0.150 |
Why?
|
Cognition Disorders | 2 | 2014 | 939 | 0.150 |
Why?
|
Immune Evasion | 1 | 2017 | 2 | 0.150 |
Why?
|
Toxoplasmosis | 2 | 2014 | 5 | 0.140 |
Why?
|
Cryptococcosis | 2 | 2014 | 5 | 0.140 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 2 | 2007 | 3 | 0.140 |
Why?
|
Disease Management | 1 | 2017 | 108 | 0.140 |
Why?
|
Fibroblasts | 2 | 2008 | 57 | 0.140 |
Why?
|
Myocarditis | 1 | 2016 | 9 | 0.140 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2016 | 1 | 0.140 |
Why?
|
Malformations of Cortical Development, Group I | 1 | 2016 | 2 | 0.140 |
Why?
|
Interleukin-7 | 1 | 2016 | 11 | 0.140 |
Why?
|
Proton-Translocating ATPases | 2 | 1995 | 5 | 0.140 |
Why?
|
Mutation | 2 | 2014 | 306 | 0.130 |
Why?
|
Myocardium | 1 | 2016 | 125 | 0.130 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2015 | 29 | 0.130 |
Why?
|
Tremor | 2 | 2021 | 116 | 0.130 |
Why?
|
Dermatologic Agents | 1 | 2015 | 7 | 0.130 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 28 | 0.130 |
Why?
|
Cross Reactions | 2 | 2021 | 10 | 0.130 |
Why?
|
Spinal Puncture | 1 | 2015 | 24 | 0.130 |
Why?
|
Intensive Care Units | 1 | 2017 | 277 | 0.120 |
Why?
|
Brain Waves | 1 | 2015 | 5 | 0.120 |
Why?
|
In Situ Hybridization | 2 | 2006 | 32 | 0.120 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2014 | 6 | 0.120 |
Why?
|
Referral and Consultation | 1 | 2015 | 74 | 0.120 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 106 | 0.120 |
Why?
|
Up-Regulation | 1 | 2015 | 131 | 0.120 |
Why?
|
Brain Mapping | 1 | 2015 | 164 | 0.120 |
Why?
|
Pancytopenia | 1 | 2014 | 2 | 0.120 |
Why?
|
Interferon beta-1a | 1 | 2014 | 2 | 0.120 |
Why?
|
Health Services Accessibility | 1 | 2015 | 94 | 0.120 |
Why?
|
Deltaretrovirus Infections | 1 | 1994 | 1 | 0.120 |
Why?
|
Simian T-lymphotropic virus 1 | 1 | 1994 | 1 | 0.120 |
Why?
|
Genes, env | 1 | 1994 | 1 | 0.120 |
Why?
|
Neisseria meningitidis | 1 | 2014 | 1 | 0.120 |
Why?
|
DNA, Protozoan | 1 | 2014 | 1 | 0.120 |
Why?
|
Blotting, Western | 1 | 2014 | 128 | 0.120 |
Why?
|
DNA, Fungal | 1 | 2014 | 2 | 0.120 |
Why?
|
Haplorhini | 1 | 1994 | 8 | 0.120 |
Why?
|
Cryptococcus | 1 | 2014 | 2 | 0.120 |
Why?
|
Streptococcus pneumoniae | 1 | 2014 | 4 | 0.120 |
Why?
|
Toxoplasma | 1 | 2014 | 6 | 0.120 |
Why?
|
Phylogeny | 3 | 2004 | 44 | 0.120 |
Why?
|
Cerebellar Ataxia | 1 | 2014 | 4 | 0.120 |
Why?
|
DNA, Bacterial | 1 | 2014 | 39 | 0.120 |
Why?
|
Statistics as Topic | 1 | 2014 | 107 | 0.120 |
Why?
|
Transplantation Conditioning | 1 | 2014 | 39 | 0.120 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 29 | 0.110 |
Why?
|
Gene Order | 1 | 2013 | 2 | 0.110 |
Why?
|
Blood Group Antigens | 1 | 2013 | 1 | 0.110 |
Why?
|
Gene Deletion | 1 | 2013 | 32 | 0.110 |
Why?
|
Kinetics | 2 | 2006 | 193 | 0.110 |
Why?
|
Perfusion Imaging | 1 | 2013 | 5 | 0.110 |
Why?
|
Leukoencephalopathies | 1 | 2013 | 9 | 0.110 |
Why?
|
Multimodal Imaging | 1 | 2013 | 20 | 0.110 |
Why?
|
Transcription, Genetic | 1 | 2013 | 86 | 0.110 |
Why?
|
Immunity, Humoral | 1 | 2013 | 3 | 0.110 |
Why?
|
Pons | 1 | 2013 | 5 | 0.110 |
Why?
|
Antigens, Differentiation | 1 | 2013 | 9 | 0.110 |
Why?
|
Mice, Inbred NOD | 1 | 2013 | 21 | 0.110 |
Why?
|
Retroviridae Proteins | 1 | 1993 | 1 | 0.110 |
Why?
|
Microscopy, Electron | 2 | 2003 | 63 | 0.110 |
Why?
|
Mice, SCID | 1 | 2013 | 27 | 0.110 |
Why?
|
RNA, Messenger | 3 | 2023 | 240 | 0.110 |
Why?
|
Cloning, Molecular | 3 | 2007 | 22 | 0.110 |
Why?
|
Sequence Analysis, DNA | 2 | 2004 | 53 | 0.110 |
Why?
|
Comorbidity | 2 | 2015 | 450 | 0.110 |
Why?
|
In Vitro Techniques | 2 | 2008 | 169 | 0.100 |
Why?
|
Radiography | 2 | 2005 | 572 | 0.100 |
Why?
|
Genes, Regulator | 1 | 2012 | 2 | 0.100 |
Why?
|
Viral Core Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
Alcoholic Intoxication | 1 | 2012 | 5 | 0.100 |
Why?
|
Viral Tropism | 1 | 2012 | 2 | 0.100 |
Why?
|
Lymphocyte Count | 2 | 2019 | 17 | 0.100 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2010 | 33 | 0.100 |
Why?
|
DNA Mutational Analysis | 1 | 2012 | 46 | 0.100 |
Why?
|
Atrophy | 1 | 2012 | 88 | 0.100 |
Why?
|
Macrophages | 1 | 1992 | 104 | 0.100 |
Why?
|
Amino Acid Motifs | 1 | 2011 | 14 | 0.100 |
Why?
|
Antiprotozoal Agents | 1 | 2011 | 8 | 0.100 |
Why?
|
Longitudinal Studies | 1 | 2015 | 1303 | 0.100 |
Why?
|
Facial Hemiatrophy | 1 | 2011 | 1 | 0.100 |
Why?
|
Cell Proliferation | 2 | 2008 | 145 | 0.090 |
Why?
|
Immunoglobulin G | 1 | 2011 | 83 | 0.090 |
Why?
|
Leukocyte Count | 2 | 2007 | 62 | 0.090 |
Why?
|
Kidney Failure, Chronic | 2 | 2020 | 140 | 0.090 |
Why?
|
Flow Cytometry | 2 | 2002 | 99 | 0.090 |
Why?
|
Antigens | 1 | 2010 | 6 | 0.090 |
Why?
|
Spleen | 1 | 2010 | 29 | 0.090 |
Why?
|
HLA-A3 Antigen | 1 | 2010 | 1 | 0.090 |
Why?
|
HLA-B18 Antigen | 1 | 2010 | 1 | 0.090 |
Why?
|
Serotyping | 1 | 2010 | 10 | 0.090 |
Why?
|
HLA-B Antigens | 1 | 2010 | 9 | 0.090 |
Why?
|
HLA-C Antigens | 1 | 2010 | 10 | 0.090 |
Why?
|
Gene Frequency | 1 | 2010 | 60 | 0.090 |
Why?
|
Lymph Nodes | 1 | 2010 | 59 | 0.090 |
Why?
|
Bone and Bones | 1 | 2010 | 107 | 0.080 |
Why?
|
Immunocompetence | 2 | 2011 | 5 | 0.080 |
Why?
|
Outpatients | 1 | 2010 | 52 | 0.080 |
Why?
|
Spinal Cord Diseases | 1 | 2010 | 45 | 0.080 |
Why?
|
Blood | 1 | 2009 | 16 | 0.080 |
Why?
|
Cerebral Angiography | 2 | 2020 | 28 | 0.080 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2009 | 11 | 0.080 |
Why?
|
Microtubule-Associated Proteins | 1 | 2009 | 19 | 0.080 |
Why?
|
Antigens, CD | 1 | 2009 | 50 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 1 | 2013 | 685 | 0.080 |
Why?
|
Pregnancy | 1 | 2009 | 302 | 0.080 |
Why?
|
Inpatients | 1 | 2010 | 127 | 0.080 |
Why?
|
Neurodegenerative Diseases | 1 | 2010 | 110 | 0.080 |
Why?
|
Pilot Projects | 1 | 2009 | 361 | 0.080 |
Why?
|
Incidence | 2 | 2022 | 665 | 0.080 |
Why?
|
Cerebrovascular Disorders | 1 | 2010 | 130 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2008 | 49 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 1 | 2010 | 380 | 0.070 |
Why?
|
Polycythemia Vera | 1 | 2007 | 2 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2007 | 24 | 0.070 |
Why?
|
Brain Neoplasms | 2 | 2002 | 71 | 0.070 |
Why?
|
Leukocyte Common Antigens | 1 | 2007 | 6 | 0.070 |
Why?
|
Receptors, CCR7 | 1 | 2007 | 7 | 0.070 |
Why?
|
Recombinant Proteins | 3 | 2016 | 186 | 0.070 |
Why?
|
Receptors, Chemokine | 1 | 2007 | 8 | 0.070 |
Why?
|
Dermatomyositis | 1 | 2006 | 11 | 0.070 |
Why?
|
Myelin Sheath | 1 | 2006 | 17 | 0.070 |
Why?
|
Cell Separation | 1 | 2005 | 25 | 0.060 |
Why?
|
Cell Movement | 1 | 2006 | 72 | 0.060 |
Why?
|
Alternative Splicing | 2 | 1997 | 15 | 0.060 |
Why?
|
Survival Analysis | 1 | 2006 | 233 | 0.060 |
Why?
|
Open Reading Frames | 3 | 1997 | 7 | 0.060 |
Why?
|
Crohn Disease | 1 | 2005 | 39 | 0.060 |
Why?
|
Antigens, Polyomavirus Transforming | 2 | 2002 | 4 | 0.060 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2004 | 1 | 0.060 |
Why?
|
Creatine | 1 | 2004 | 4 | 0.060 |
Why?
|
Plant Proteins | 1 | 2004 | 1 | 0.060 |
Why?
|
Immunodominant Epitopes | 1 | 2004 | 1 | 0.060 |
Why?
|
Consensus Sequence | 1 | 2004 | 1 | 0.060 |
Why?
|
Choline | 1 | 2004 | 5 | 0.060 |
Why?
|
Trans-Activators | 1 | 2004 | 20 | 0.060 |
Why?
|
Cytomegalovirus | 1 | 2004 | 12 | 0.060 |
Why?
|
HeLa Cells | 2 | 1995 | 39 | 0.060 |
Why?
|
Central Nervous System | 1 | 2004 | 46 | 0.060 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2004 | 4 | 0.060 |
Why?
|
Mefloquine | 2 | 2016 | 2 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2004 | 116 | 0.060 |
Why?
|
Muscle, Skeletal | 2 | 2004 | 329 | 0.060 |
Why?
|
Endothelial Cells | 1 | 2004 | 57 | 0.060 |
Why?
|
Heart | 1 | 2004 | 70 | 0.060 |
Why?
|
Inclusion Bodies, Viral | 1 | 2003 | 1 | 0.060 |
Why?
|
Immunophenotyping | 1 | 2003 | 27 | 0.060 |
Why?
|
Organ Specificity | 1 | 2003 | 39 | 0.060 |
Why?
|
Immunization, Secondary | 1 | 2023 | 4 | 0.050 |
Why?
|
DNA Primers | 1 | 2003 | 45 | 0.050 |
Why?
|
Antibodies, Neutralizing | 1 | 2023 | 21 | 0.050 |
Why?
|
Antibodies | 1 | 2023 | 36 | 0.050 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 14 | 0.050 |
Why?
|
RNA Splicing | 2 | 1992 | 10 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2004 | 250 | 0.050 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2002 | 1 | 0.050 |
Why?
|
Medulloblastoma | 1 | 2002 | 6 | 0.050 |
Why?
|
DNA, Neoplasm | 1 | 2002 | 16 | 0.050 |
Why?
|
Cystitis | 1 | 2002 | 11 | 0.050 |
Why?
|
Virus Shedding | 1 | 2022 | 5 | 0.050 |
Why?
|
Anxiety | 1 | 2023 | 136 | 0.050 |
Why?
|
Rural Population | 1 | 2022 | 23 | 0.050 |
Why?
|
Homosexuality | 2 | 1993 | 6 | 0.050 |
Why?
|
Epitope Mapping | 1 | 2021 | 1 | 0.050 |
Why?
|
Hemorrhage | 1 | 2002 | 72 | 0.050 |
Why?
|
Cohort Studies | 2 | 2019 | 1758 | 0.050 |
Why?
|
Mice, Inbred BALB C | 1 | 2021 | 79 | 0.050 |
Why?
|
Vaccination | 1 | 2021 | 29 | 0.050 |
Why?
|
Extracellular Vesicles | 1 | 2021 | 2 | 0.050 |
Why?
|
Reoperation | 3 | 2017 | 807 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 2 | 1999 | 52 | 0.050 |
Why?
|
Nerve Growth Factor | 1 | 2001 | 26 | 0.050 |
Why?
|
Income | 1 | 2022 | 70 | 0.050 |
Why?
|
Vascular Diseases | 1 | 2001 | 44 | 0.050 |
Why?
|
Syphilis Serodiagnosis | 1 | 2021 | 2 | 0.050 |
Why?
|
Fluorescent Treponemal Antibody-Absorption Test | 1 | 2021 | 2 | 0.050 |
Why?
|
Phrenic Nerve | 1 | 2021 | 2 | 0.050 |
Why?
|
Serotonin Syndrome | 1 | 2021 | 1 | 0.050 |
Why?
|
Diaphragm | 1 | 2021 | 8 | 0.050 |
Why?
|
Myoclonus | 1 | 2021 | 11 | 0.050 |
Why?
|
Epithelial Cells | 1 | 2021 | 76 | 0.050 |
Why?
|
Ultrasonography, Doppler, Transcranial | 1 | 2020 | 5 | 0.050 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2020 | 14 | 0.050 |
Why?
|
Point-of-Care Testing | 1 | 2021 | 29 | 0.050 |
Why?
|
Brain Stem | 1 | 2020 | 20 | 0.050 |
Why?
|
Drug Interactions | 1 | 2020 | 36 | 0.050 |
Why?
|
Peripheral Nerves | 1 | 2020 | 17 | 0.050 |
Why?
|
Tertiary Care Centers | 1 | 2021 | 61 | 0.050 |
Why?
|
Thrombectomy | 1 | 2020 | 28 | 0.050 |
Why?
|
Patient Positioning | 1 | 2020 | 38 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2001 | 139 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 34 | 0.040 |
Why?
|
Mice, Inbred C57BL | 1 | 2021 | 359 | 0.040 |
Why?
|
Child, Preschool | 1 | 2022 | 588 | 0.040 |
Why?
|
Skin | 1 | 2001 | 102 | 0.040 |
Why?
|
Anticoagulants | 1 | 2020 | 84 | 0.040 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 3 | 0.040 |
Why?
|
Penicillins | 1 | 2019 | 7 | 0.040 |
Why?
|
HTLV-I Infections | 3 | 1997 | 4 | 0.040 |
Why?
|
Blotting, Southern | 1 | 1999 | 3 | 0.040 |
Why?
|
Homosexuality, Male | 1 | 2019 | 23 | 0.040 |
Why?
|
Granulocytes | 1 | 1999 | 13 | 0.040 |
Why?
|
Head | 1 | 2019 | 21 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 1999 | 40 | 0.040 |
Why?
|
Hospitalization | 1 | 2022 | 282 | 0.040 |
Why?
|
Ultrasonography | 1 | 2021 | 219 | 0.040 |
Why?
|
Neurobiology | 1 | 2019 | 5 | 0.040 |
Why?
|
Monocytes | 1 | 1999 | 58 | 0.040 |
Why?
|
Gait | 1 | 2022 | 391 | 0.040 |
Why?
|
Vacuoles | 2 | 1995 | 5 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 167 | 0.040 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 36 | 0.040 |
Why?
|
Linear Models | 1 | 1999 | 231 | 0.040 |
Why?
|
Cell Transformation, Viral | 2 | 1997 | 3 | 0.040 |
Why?
|
Phlebography | 1 | 2017 | 9 | 0.040 |
Why?
|
Magnetic Resonance Angiography | 1 | 2017 | 24 | 0.040 |
Why?
|
Sequence Homology, Amino Acid | 2 | 1994 | 28 | 0.040 |
Why?
|
Species Specificity | 2 | 1994 | 40 | 0.040 |
Why?
|
Body Mass Index | 1 | 2019 | 395 | 0.040 |
Why?
|
Nephrectomy | 1 | 2017 | 28 | 0.040 |
Why?
|
Age Factors | 1 | 2019 | 721 | 0.040 |
Why?
|
Gene Products, rex | 2 | 1997 | 2 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 151 | 0.040 |
Why?
|
Ipilimumab | 1 | 2016 | 4 | 0.030 |
Why?
|
Heart Block | 1 | 2016 | 5 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2016 | 14 | 0.030 |
Why?
|
Ocular Motility Disorders | 1 | 1996 | 1 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2016 | 60 | 0.030 |
Why?
|
Eye Movements | 1 | 1996 | 13 | 0.030 |
Why?
|
Melanoma | 1 | 2016 | 50 | 0.030 |
Why?
|
Mesencephalon | 1 | 1996 | 22 | 0.030 |
Why?
|
Electrocardiography | 1 | 2016 | 112 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2016 | 87 | 0.030 |
Why?
|
Myositis | 1 | 2016 | 34 | 0.030 |
Why?
|
Intracellular Membranes | 1 | 1995 | 31 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1995 | 30 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2015 | 129 | 0.030 |
Why?
|
Chronic Disease | 1 | 2016 | 407 | 0.030 |
Why?
|
Cercopithecidae | 1 | 1994 | 1 | 0.030 |
Why?
|
Sequence Analysis | 1 | 1994 | 3 | 0.030 |
Why?
|
Cytoplasmic Granules | 1 | 2014 | 5 | 0.030 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1994 | 7 | 0.030 |
Why?
|
Pan troglodytes | 1 | 1994 | 7 | 0.030 |
Why?
|
Electronystagmography | 2 | 1991 | 2 | 0.030 |
Why?
|
Audiometry | 2 | 1991 | 4 | 0.030 |
Why?
|
Rituximab | 1 | 2014 | 45 | 0.030 |
Why?
|
Allografts | 1 | 2014 | 187 | 0.030 |
Why?
|
HTLV-I Antigens | 1 | 1993 | 1 | 0.030 |
Why?
|
Cell Compartmentation | 1 | 1993 | 10 | 0.030 |
Why?
|
White Matter | 1 | 2015 | 143 | 0.030 |
Why?
|
Leukemia, T-Cell | 1 | 1992 | 1 | 0.030 |
Why?
|
Paraparesis, Tropical Spastic | 1 | 1992 | 1 | 0.030 |
Why?
|
HIV Core Protein p24 | 1 | 1992 | 11 | 0.030 |
Why?
|
Genes, Overlapping | 1 | 1992 | 1 | 0.030 |
Why?
|
Gene Products, tax | 1 | 1992 | 2 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1992 | 5 | 0.030 |
Why?
|
Gene Products, env | 1 | 1992 | 13 | 0.030 |
Why?
|
Gait Disorders, Neurologic | 1 | 2014 | 139 | 0.030 |
Why?
|
Oligoclonal Bands | 1 | 2011 | 1 | 0.020 |
Why?
|
Databases, Factual | 1 | 2013 | 306 | 0.020 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2011 | 7 | 0.020 |
Why?
|
United States | 1 | 2017 | 1901 | 0.020 |
Why?
|
Vasculitis | 1 | 1991 | 26 | 0.020 |
Why?
|
Hearing Disorders | 1 | 1991 | 2 | 0.020 |
Why?
|
Vestibular Diseases | 1 | 1991 | 4 | 0.020 |
Why?
|
Reference Values | 1 | 2011 | 185 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 1991 | 35 | 0.020 |
Why?
|
Evoked Potentials, Visual | 1 | 1990 | 2 | 0.020 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 1990 | 8 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2015 | 1191 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 1990 | 22 | 0.020 |
Why?
|
Serotonin Antagonists | 1 | 2008 | 9 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2008 | 87 | 0.020 |
Why?
|
Antigen-Antibody Reactions | 1 | 2007 | 5 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 209 | 0.020 |
Why?
|
Cytarabine | 1 | 2006 | 11 | 0.020 |
Why?
|
Cognition | 1 | 2015 | 1273 | 0.020 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2006 | 6 | 0.020 |
Why?
|
Peptides | 1 | 2007 | 93 | 0.020 |
Why?
|
Cytokines | 1 | 2007 | 201 | 0.020 |
Why?
|
Preventive Medicine | 1 | 2004 | 7 | 0.010 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2004 | 28 | 0.010 |
Why?
|
Graft Rejection | 1 | 2004 | 62 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2002 | 36 | 0.010 |
Why?
|
Endothelium | 1 | 2001 | 11 | 0.010 |
Why?
|
Muscle Weakness | 1 | 2001 | 28 | 0.010 |
Why?
|
Edema | 1 | 2001 | 24 | 0.010 |
Why?
|
Pain Measurement | 1 | 2001 | 426 | 0.010 |
Why?
|
Didanosine | 1 | 1997 | 3 | 0.010 |
Why?
|
Zidovudine | 1 | 1997 | 14 | 0.010 |
Why?
|
Hearing Tests | 1 | 1997 | 8 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1997 | 59 | 0.010 |
Why?
|
Double-Blind Method | 1 | 1997 | 413 | 0.010 |
Why?
|
Blepharoptosis | 1 | 1996 | 1 | 0.010 |
Why?
|
Convergence, Ocular | 1 | 1996 | 1 | 0.010 |
Why?
|
Exotropia | 1 | 1996 | 1 | 0.010 |
Why?
|
Ophthalmoplegia | 1 | 1996 | 2 | 0.010 |
Why?
|
Americas | 1 | 1994 | 1 | 0.010 |
Why?
|
Bovine papillomavirus 1 | 1 | 1993 | 1 | 0.010 |
Why?
|
Biological Evolution | 1 | 1993 | 8 | 0.010 |
Why?
|
AIDS-Related Complex | 1 | 1991 | 2 | 0.010 |
Why?
|
Vestibular Function Tests | 1 | 1991 | 2 | 0.010 |
Why?
|
Evoked Potentials, Auditory, Brain Stem | 1 | 1991 | 4 | 0.010 |
Why?
|